To include your compound in the COVID-19 Resource Center, submit it here.

Cebranopadol: Phase III data

The double-blind, international Phase III CORAL trial in 125 patients with moderate to severe chronic cancer pain currently on opioid treatment showed that once-daily oral cebranopadol met the primary endpoint of non-inferiority to twice-daily oral

Read the full 356 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers